EQS-News: Cantourage Strengthens Capital Markets Presence: New Head of Investor Relations and Strategic Focus on Europe

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notices at the end of this release must be observed.

Berlin, October 1, 2025 – Cantourage Group SE (ISIN: DE000A3DSV01, “Cantourage”) today announced a significant step in expanding its capital markets presence. Manuel Taverne, a seasoned capital markets professional, has been appointed as Head of Investor Relations. In this role, he will lead Cantourage’s investor relations activities with a particular focus on strengthening engagement across European financial markets.

With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.

“By bringing Manuel Taverne on board, we gain an accomplished capital markets expert with outstanding knowledge and extensive experience. I am excited to work with him as we continue to expand our investor engagement,” said Philip Schetter, CEO of Cantourage.

Cantourage’s goal is to more clearly communicate its position as one of Europe’s leading providers of medical cannabis to the investment community. “Our innovative business model and platform strategy set us apart from the competition – yet the uniqueness of our approach has not been fully recognized by the market to date,” Schetter continued. “That is why we are intensifying our investor relations efforts – to present our equity story with greater clarity, transparency, and proactivity.”

About Cantourage

Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022 and is listed under the ticker symbol “HIGH”.

More information: www.cantourage.com

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning ofRegulation (EU) 2017/1129 (Prospectus Regulation).